Insider Selling: Charles River Laboratories International, Inc. (NYSE:CRL) Director Sells 3,830 Shares of Stock

Charles River Laboratories International, Inc. (NYSE:CRL) Director George Massaro sold 3,830 shares of Charles River Laboratories International stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $100.81, for a total transaction of $386,102.30. Following the sale, the director now owns 18,731 shares in the company, valued at $1,888,272.11. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

George Massaro also recently made the following trade(s):

• On Friday, May 12th, George Massaro sold 1,130 shares of Charles River Laboratories International stock. The stock was sold at an average price of $88.30, for a total transaction of $99,779.00.

Charles River Laboratories International, Inc. (CRL) opened at 99.60 on Tuesday. The firm’s 50-day moving average is $99.43 and its 200 day moving average is $90.83. The company has a market cap of $4.74 billion, a price-to-earnings ratio of 29.15 and a beta of 1.02. Charles River Laboratories International, Inc. has a 12-month low of $67.20 and a 12-month high of $102.32.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, May 10th. The medical research company reported $1.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.15. The firm had revenue of $445.80 million during the quarter, compared to analyst estimates of $437.04 million. Charles River Laboratories International had a return on equity of 27.46% and a net margin of 9.28%. The business’s quarterly revenue was up 25.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.98 earnings per share. On average, equities analysts expect that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current fiscal year.

Charles River Laboratories International announced that its board has authorized a share repurchase plan on Wednesday, May 10th that authorizes the company to buyback $150.00 million in shares. This buyback authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Shares buyback plans are usually an indication that the company’s board believes its stock is undervalued.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by [[site]] and is the sole property of of [[site]]. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at [[permalink]].

Several hedge funds have recently added to or reduced their stakes in the stock. Private Trust Co. NA acquired a new stake in shares of Charles River Laboratories International during the first quarter worth approximately $473,000. Copper Rock Capital Partners LLC raised its stake in shares of Charles River Laboratories International by 31.6% in the first quarter. Copper Rock Capital Partners LLC now owns 314,182 shares of the medical research company’s stock worth $28,157,000 after buying an additional 75,516 shares during the last quarter. Charter Trust Co. raised its stake in shares of Charles River Laboratories International by 4.6% in the first quarter. Charter Trust Co. now owns 3,030 shares of the medical research company’s stock worth $272,000 after buying an additional 134 shares during the last quarter. Peregrine Capital Management LLC acquired a new stake in shares of Charles River Laboratories International during the first quarter worth approximately $7,971,000. Finally, Foundry Partners LLC raised its stake in shares of Charles River Laboratories International by 3.3% in the first quarter. Foundry Partners LLC now owns 89,085 shares of the medical research company’s stock worth $8,013,000 after buying an additional 2,872 shares during the last quarter. 95.81% of the stock is owned by hedge funds and other institutional investors.

Several research firms recently commented on CRL. Barclays PLC set a $90.00 target price on shares of Charles River Laboratories International and gave the stock a “hold” rating in a research report on Saturday, May 13th. Zacks Investment Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $111.00 target price on the stock in a research report on Wednesday, July 12th. Jefferies Group LLC reiterated a “buy” rating and set a $121.00 target price on shares of Charles River Laboratories International in a research report on Friday, June 30th. Credit Suisse Group reiterated a “neutral” rating and set a $95.00 target price (up from $89.00) on shares of Charles River Laboratories International in a research report on Tuesday, June 6th. Finally, BidaskClub upgraded shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, June 20th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the stock. Charles River Laboratories International presently has an average rating of “Hold” and a consensus target price of $97.06.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.